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Supplementation with a selective 
amino acid formula ameliorates 
muscular dystrophy in mdx mice
Stefania Banfi1, Giuseppe D’Antona2, Chiara Ruocco3, Mirella Meregalli1, Marzia Belicchi1, 
Pamela Bella1, Silvia Erratico4, Elisa Donato  5,6,7, Fabio Rossi3, Francesco Bifari  8, 
Caterina Lonati9, Stefano Campaner5, Enzo Nisoli  3 & Yvan Torrente1
Duchenne muscular dystrophy (DMD) is one of the most common and severe forms of muscular 
dystrophy. Oxidative myofibre content, muscle vasculature architecture and exercise tolerance are 
impaired in DMD. Several studies have demonstrated that nutrient supplements ameliorate dystrophic 
features, thereby enhancing muscle performance. Here, we report that dietary supplementation with a 
specific branched-chain amino acid-enriched mixture (BCAAem) increased the abundance of oxidative 
muscle fibres associated with increased muscle endurance in dystrophic mdx mice. Amelioration 
of the fatigue index in BCAAem-treated mdx mice was caused by a cascade of events in the muscle 
tissue, which were promoted by endothelial nitric oxide synthase (eNOS) activation and vascular 
endothelial growth factor (VEGF) expression. VEGF induction led to recruitment of bone marrow (BM)-
derived endothelial progenitors (EPs), which increased the capillary density of dystrophic skeletal 
muscle. Functionally, BCAAem mitigated the dystrophic phenotype of mdx mice without inducing 
dystrophin protein expression or replacing the dystrophin-associated glycoprotein (DAG) complex in 
the membrane, which is typically lost in DMD. BCAAem supplementation could be an effective adjuvant 
strategy in DMD treatment.
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy are caused by mutations within the dys-
trophin gene1 which primarily results in sarcolemmal fragility, muscle damage and respiratory or cardiac muscle 
fatigue and failure2,3. Treatment strategies for DMD have been done using genetic4–9, pharmacological10,11, or 
cellular12–16 approaches aimed at restoring dystrophin-associated glycoprotein (DAG) complex, reversing sar-
colemmal fragility, and abating muscular dystrophy. However many hurdles remain and DMD is still incurable. 
Dysregulation of pathways associated with muscle fibre plasticity and angiogenesis in DMD are not well under-
stood. Elucidation of such pathways may reveal signalling targets that are amenable to therapeutic manipula-
tion by synthetic drugs. Activation of AMP-activated protein kinase (AMPK) ameliorates DMD mitochondrial 
activity and promotes oxidative slow-twitch myogenesis in mdx mice17,18. The transcription factor peroxisome 
proliferator-activated receptor γ coactivator-1α (PGC-1α) regulates the neuromuscular junction gene pro-
gramme, induces a fast-to-slow fibre type transition, and ameliorates DMD pathology19,20. The dystrophin protein 
is expressed not only in skeletal muscle cells but also in vascular smooth muscle and endothelial cells (ECs)21,22. 
Vascular defects, including ultrastructural abnormalities of microvessels, mixed degenerating and regenerating 
capillaries, replication of the capillary basal lamina, and compression of capillaries and small-calibre veins by 
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nodular proliferative connective tissue, have been described in DMD muscles23–25. Angiogenic factors, such as 
VEGF stimulate muscle regeneration in DMD26–28. Based on the benefits of pro-oxidative and angiogenic regula-
tion in muscular dystrophy, we and other groups introduced the concept of dietary supplementation to ameliorate 
dystrophic muscle pathology29,30. Creatine, taurine, l-glutamine, and l-arginine have been shown to have limited 
benefits on muscle strength and dystrophic features, though these supplements remain to be formally evaluated 
in long-term studies31–34.
Angiogenesis in skeletal muscle is regulated by nitric oxide (NO) produced by endothelial nitric oxide synthase 
(eNOS), neuronal NOS (nNOS)35,36, inducible NOS (iNOS). All of these isoforms are expressed in muscle, and 
nNOS, in particular, is abundant at the surfaces of type II (fast-twitch) fibres, and less so in type I (slow-twitch) 
fibres, bound to the sarcolemma via the dystrophin-glycoprotein complex. On the other hand, eNOS is expressed 
on the cell surfaces of ECs in a complex with caveolin-1 and dystrophin and in type I fibres mitochondrial mem-
brane level37,38. In both cases, several reports have shown that oestrogens, via oestrogen-related receptor-α 
(ER-α), can upregulate eNOS mRNA and protein levels, increasing the phosphorylation of eNOS via specific 
kinases39. Dystrophin deficiency induces a selective defect in flow-dependent mechanotransduction, thus atten-
uating flow (shear stress)-mediated endothelium-dependent dilation (FMD) and eNOS expression, and may 
contribute to low arteriolar density40. Furthermore, eNOS deletion in skeletal muscle impairs muscle perfor-
mance41. We have demonstrated that eNOS is involved in the effect of dietary supplementation with a selective 
branched-chain amino acid-enriched mixture (BCAAem) on PGC-1α and sirtuin 1 expression in cardiac and 
skeletal muscles of middle-aged mice42. Here, we describe for the first time that BCAAem promotes muscle repair 
by increasing oxidative fibre content and angiogenic remodelling in dystrophic skeletal muscle in mdx mice. We 
found a prevalence of myosin heavy chain (MyHC) type IIx aerobic/glycolytic and MyHC type IIb glycolytic 
muscle fibres in the BCAAem-treated mdx muscles associated with increased response to fatigue. We demon-
strate that the molecular mechanism underlying BCAAem action is based on augmented eNOS expression and 
phosphorylation and with increased synthesis of VEGF and recruitment of bone-marrow-derived Sca1+CD34+ 
endothelial progenitors to dystrophic muscles. This BCAAem response determines the microvasculature reorgan-
ization of dystrophic mdx skeletal muscle. The pivotal role of eNOS in mediating the effects of BCAAem on EC 
compartments was demonstrated by the absence of a BCAAem response in eNOS null mutant mice (eNOS−/−). 
The increase in oxidative muscle fibre content and the angiogenic remodelling mediated by BCAAem mitigate 
muscle damage in mdx mice, supporting the notion that dietary supplementation with BCAAem is an effective 
adjuvant strategy for DMD treatment.
Results
BCAAem induces an increase in oxidative fibre content in skeletal muscles of mdx mice. To 
study the effects of BCAAem supplementation on muscular dystrophy, we administered the amino acid mixture 
(1.5 mg/g body weight) with drinking water to 3-month-old mdx mice for two weeks. This genetically dystrophic 
mouse model exhibits dystrophic muscle features and skeletal muscle vascular regression22,40,43,44. Since a greater 
level of muscular damage and fibrosis have been found in ageing female mdx mice than in males45,46, all groups of 
animals were equally divided into males and females and separately analysed. BCAAem-treated male (n = 5) and 
female (n = 5) mdx mice were compared to age-matched untreated male (n = 5) and female (n = 5) mdx mice and 
to BCAAem-treated and untreated wild-type C57BL6/J and eNOS−/− mice (5 males and 5 females in each group) 
(Figs 1 and S2). eNOS−/− mice were included in this study because we previously reported that BCAAem treat-
ment increased eNOS expression and activation (eNOS-Ser1177 phosphorylation) in cardiomyocytes, whereas 
eNOS KO cells were insensitive to BCAAem42.
We measured the circulating BCAA (leucine, isoleucine, and valine) levels in mdx, wild-type (C57BL6/J) and 
eNOS−/− mice acutely (30–120 min) supplemented with BCAAem as previously described42. The BCAA levels in 
the plasma of C57BL6/J and mdx mice had superimposable kinetics (Fig. S1). Moreover, we have demonstrated 
that water consumption was the same by all untreated and BCAAem-treated mice (Fig. S1).
Morphometric analysis of the tibialis anterior (TA) and vastus medialis (VM) muscles of BCAAem-treated 
mdx mice did not show reduction in the levels of the typical fibrotic infiltrate and centrally nucleated fibres 
(Fig. 1a, b). Mdx mice were characterized by a high variability in myofibre size (Fig. 1c, d). The cross-sectional 
areas (CSAs) of the myofibres observed in the muscles of BCAAem-treated mdx females (TA: 2792 ± 53 μm2, 
n = 5; VM: 1329 ± 27 μm2, n = 5) were significantly lower than those observed in the muscles of untreated mice 
(TA: 4519 ± 98 μm2, n = 5; VM: 1564 ± 20 μm2, n = 5) (p < 0.0001, one-way analysis of variance (ANOVA) 
with Bonferroni correction). Although not significant, similar reduction in CSAs was observed in the mus-
cles of BCAAem-treated mdx males (TA: 2945 ± 44.79 μm2, n = 5; VM: 1538 ± 22 μm2, n = 5) compared to 
the CSAs observed in the muscles of untreated mdx males (TA: 4206 ± 88.4 μm2, n = 5; VM: 1571 ± 30 μm2, 
n = 5) (Fig. 1e, f). Moreover, the coefficient of variation in myofibre area was significantly higher for the mus-
cles of BCAAem-treated mdx male and female mice (TA: 67.14 ± 5.35% for males and 48 ± 3.12% for females; 
VM: 69 ± 4.75% for males and 52 ± 4.23% for females) than for those of untreated mdx male and female mice 
(TA: 51.32 ± 7% for males and 50.73 ± 2.5% for females; VM: 40 ± 3.88% for males and 52 ± 4.23% for females) 
(p < 0.0001, F-test of variance). Histological, biochemical, and morphometric analyses of BCAAem-treated and 
untreated eNOS−/− mice revealed unmodified muscle phenotypes (Fig. S2). In particular, the areas of the muscle 
fibres of BCAAem-treated eNOS−/− mice (TA: 2103 ± 42 μm2 for males and 2159 ± 55 μm2 for females; VM: 
2374 ± 45 μm2 for males and 2111 ± 39 μm2 for females) were similar to those observed in untreated mice (TA: 
1905 ± 46 μm2 for males and 1886 ± 32 μm2 for females; VM: 2489 ± 63 μm2 for males and 2075 ± 41 μm2 for 
females) (Fig. S2g–j). However, a statistically significant reduction in CSA values was also observed for the TA 
(1813 ± 19 μm2, n = 5) and VM (2476 ± 27 μm2) muscles of BCAAem-treated male C57BL6/J mice compared to 
the CSAs of untreated TA (1871 ± 22.5 μm2) and VM (2679 ± 55 μm2) muscles of C57BL6/J males, with a similar 
trend observed for females (TA: untreated 2951 ± 68 μm2 vs. treated 2110 ± 51 μm2; VM: untreated 2479 ± 50 μm2 
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vs. treated 2687 ± 48 μm2) (p < 0.001, one-way ANOVA with Bonferroni correction) (Fig. S2k, l). Changes in the 
CSAs of the muscles of dystrophic mdx and wild-type C57BL6/J mice suggest the existence of a muscle remod-
elling process induced by BCAAem that could be associated with a change in muscle fibre content. Because 
the myosin motor protein is closely associated with sex-based differences in muscle function, we verified the 
fibre composition of both sexes in untreated and BCAAem-treated mice. We observed a statistically significant 
increase in the expression of the MyHC IIx (oxidative/glycolytic type IIx myofibres) protein in the TAs and VMs 
of BCAAem-treated mdx females and the TAs of mdx males, whereas MyHC IIb (glycolytic type IIb myofibres) 
expression was significantly increased in the TAs of BCAAem-treated mdx males and VMs of BCAAem-treated 
mdx females (p < 0.05, one-way ANOVA with Bonferroni correction) (Fig. 2a). To confirm these findings, myofi-
brillar adenosine triphosphatase (mATPase) activity was evaluated at pH 4.3 by using an enzymatic stain that 
distinguishes between slow and fast glycolytic myofibres (Fig. 2b–d). Similar to the ATPase assay, Succinate 
Dehydrogenase (SDH) activity was tested to verify the distribution of fast and slow myofibers (Fig. 2c). ATPase 
staining confirmed the statistically significant increase in MyHC IIx levels (p < 0.001, two-way ANOVA with 
Figure 1. Haematoxylin and eosin (H&E) and Azan-Mallory (AM) analysis of BCAAem-treated and 
untreated mdx male and female mice. Representative H&E and AM staining of vastus medialis (VM) (a) and 
tibialis anterior (TA) (b) of untreated and BCAAem-treated mdx male and female mice. Scale bars, 200 μm. 
Quantification of the relative frequency of the myofibre cross-sectional area (CSA) expressed as the frequency 
distribution of the VM (c,e) and TA (d,f) muscles of the untreated and treated experimental groups of male and 
female mice. Boxes indicate 25th to 75th percentiles; whiskers indicate 5th to 95th percentiles and the line indicates 
the median (n = 5 per group). Statistical error analysis was performed by two-way ANOVA with Bonferroni 
correction; ****p < 0.0001 for the indicated comparisons.
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Bonferroni correction) in males and in the levels of both MyHC IIx and MyHC IIb myofibres (p < 0.001, two-way 
ANOVA with Bonferroni correction) in females of the BCAAem-treated group compared with the untreated mdx 
mice (Fig. 2b–d). All these results were confirmed by RT-PCR analysis of the MYH 1, 2, and 4 genes (Fig. 2e). To 
Figure 2. Characterization of the MyHC isoforms in the muscles of BCAAem-treated and untreated mdx mice. 
Cropped image of a representative Coomassie-Blue-stained protein gel showing electrophoretic separation of 
the MyHC IIx and IIb isoforms from the total protein lysates of VM and TA muscles of male and female mdx 
mice. (a) Cropped image of a western blot of β-actin from the total protein lysates of VM and TA muscles of 
male and female mdx mice. (a) Full-length Coomassie-stained gels and blots are presented in Supplementary 
Fig. S8. Quantification of the myosin/actin ratio to describe the different amounts of myosin isoforms. (a) 
Whole field (b) (scale bar, 500 µm) and higher magnification (c) (scale bar, 50 µm) of ATPase (pH 4.3) (left) and 
SDH-stained (right, scale bar, 100 µm) sections for detection of the distribution and composition of myosin 
heavy chain (MyHC) isoforms (d) of BCAAem-treated and untreated mdx groups. qRT-PCR quantification 
analysis of expression of the MYH1, MYH2 and MYH4 genes in the VM and TA muscles of BCAAem-
treated and untreated male and female mdx mice (n = 5 per group) normalized to expression of the GAPDH 
housekeeping gene. (e) Fast MyHC isoform immunofluorescence staining of BCAAem-treated and untreated 
VM and TA mdx male and female muscle sections (f) (scale bar 100 µm). The fast MyHC isoform fluorescence 
was quantified with the ImageJ software 6.0 and the corresponding histograms are reported as percentage 
of positive fibers per section. (g) All the experiments were conducted in triplicate. All data are presented as 
the mean ± s.e.m. Statistical error analysis was performed by two-way ANOVA with Bonferroni correction; 
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 indicate comparisons that reflect significant differences 
relative to the untreated group.
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elaborate, the levels of MYH1, which encodes the MyHC IIx isoform, were significantly increased in the TA and 
VM muscles of BCAAem-treated mdx mice of both sexes. Immunofluorescence analysis was also performed to 
measure the proportions of oxidative/slow and glycolytic/fast myofibres in the TA and VM muscles of male and 
female mdx mice. The number of slow MyHC isoforms was statistically significant higher (p < 0.0001, two-way 
ANOVA with Bonferroni correction) in the TAs and VMs of BCAAem-treated mice than in untreated female 
mdx mice, whereas significant increase was observed in the TAs of BCAAem-treated male mdx mice (p < 0.05, 
two-way ANOVA with Bonferroni correction) (Fig. S3). Conversely, the number of fast/glycolytic myofibres was 
significantly increased in the TAs of male and VMs of female BCAAem-treated mdx mice than untreated mice 
(Fig. 2f, g; p < 0.05 and p < 0.01 respectively, two-way ANOVA with Bonferroni correction). Taken together, these 
results suggest that BCAAem supplementation promotes an increase in the oxidative/glycolytic type IIx and gly-
colytic MyHC IIb content of mdx males and females.
BCAAem ameliorates the motor function of mdx mice. Then, we verified whether the increased pro-
portion of myofibres expressing type IIx and IIb myosin, promoted by the dietary BCAAem supplementation, led 
to sustained recovery of muscle function in muscular dystrophy. Overall, motor capacity was assessed in terms 
of time to exhaustion and endurance time with treadmill performance47 in three-month-old C57BL6/J (n = 5; 
3 females and 2 males), mdx (n = 5; 3 females and 2 males), and eNOS−/− (n = 5; 3 females and 2 males) mice. 
There was no clear amelioration in time to exhaustion after BCAAem administration in any of the analysed gen-
otypes (Fig. 3a). Notably, the endurance time was ameliorated in BCAAem-treated mdx mice, with an increase 
of ~20% compared to the endurance time of untreated mdx animals (38.40 ± 2.98 min vs. 48.60 ± 3.12 min in 
untreated and treated males, respectively; 38 ± 2.76 min vs. 49.40 ± 3.33 min in untreated and treated females, 
respectively; mean ± s.e.m.; p < 0.05, two-way ANOVA with Bonferroni correction) (Fig. 3b). Conversely, amino 
acid supplementation was unable to increase the exhaustion time and endurance of both C57BL6/J and eNOS−/− 
mice (Fig. 3a). Moreover, the normalized tetanic force and fatigue index were measured in isolated TA muscles 
obtained from mice of all genotypes. Mdx and eNOS−/− mice showed lower basal values of TA-specific force than 
C57BL6/J mice (Fig. 3c) and did not show any significant amelioration after BCAAem treatment. Moreover, 
C57BL6/J mice did not show any improvement in TA-specific force after BCAAem treatment. Amelioration 
of tetanic force was evident at high stimulation frequency in both female (p < 0.01, two-way ANOVA with 
Bonferroni correction) and male (p < 0.05, two-way ANOVA with Bonferroni correction) BCAAem-treated mdx 
mice (Fig. 3d). BCAAem supplementation was unable to improve motor function in eNOS−/− mice, suggesting 
that eNOS may be associated with the beneficial effects of amino acid supplementation (Fig. 3a–d). These data 
suggest that the difference in MyHC content observed between BCAAem-treated mdx males and females is not 
the only explanation for the motor function amelioration observed in BCAAem-treated mdx mice.
BCAAem modulates the expression of eNOS and VEGF in dystrophic skeletal muscle of mdx 
mice. Since skeletal muscle is an oestrogen-responsive tissue with high expression of oestrogen receptor α 
(ERα)48–50 and to explain the prevalence in females of myofibres expressing type IIx and IIb myosins, which 
are associated with ameliorated endurance time in BCAAem-treated mdx mice, we compared the ERα expres-
sion levels in BCAAem-treated mdx males and females51–53. ERα protein expression was significantly higher 
Figure 3. BCAAem ameliorates fatigue resistance in mdx mice. In vivo muscle function was determined by an 
incremental treadmill exhaustion test. Exhaustion time is expressed in min (n = 10; five females and five males 
for each genotype). (a) In vivo endurance time is expressed in min. (b) Muscle function was evaluated in vitro 
by measuring the tetanic force (g/µL) of single fibres isolated from TA strips. (c) Fatigue index, defined as the 
decrease in tetanic force at different stimulation frequencies (from 0.03 to 0.3 Hz), is compared to the maximal 
tetanic force (Tf) and expressed as a percentage. Frequency 0.3 Hz; *p < 0.05 for untreated vs. BCAAem-treated 
mdx male mice; **p < 0.01 for untreated vs. BCAAem-treated mdx female mice. (d) All data are presented as 
the mean ± s.e.m. Statistical error analysis was performed by two-way ANOVA with Bonferroni correction.
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in the TA muscles (p < 0.05, two-way ANOVA with Bonferroni correction) and higher in the VM muscles of 
BCAAem-treated mice than in untreated female mdx mice (Fig. 4a ,b). ERα protein expression was higher but 
not significantly different in the TA (p = 0.35, two-way ANOVA with Bonferroni correction) and VM (p = 0.72, 
two-way ANOVA with Bonferroni correction) muscles of BCAAem-treated mice than in untreated male mdx 
mice. The stimulatory effect of oestrogens and ERα on the release of several endothelial mediators, especially NO, 
has been well described54. Thus, we sought to investigate the effect of BCAAem supplementation on eNOS activa-
tion and the downstream signalling pathway. We performed a series of immunoblot assays on BCAAem-treated 
and untreated mdx mice. In response to amino acid supplementation, a statistically significant increase in eNOS 
expression was evident in the VM muscles of both male (p < 0.05, two-way ANOVA with Bonferroni correc-
tion) and female (p < 0.001, two-way ANOVA with Bonferroni correction) mdx mice and in the TA muscles 
(p < 0.05 two-way ANOVA with Bonferroni correction) (Fig. 4a, b) of male mdx mice. These responses were asso-
ciated with increased eNOS phosphorylation (1170Ser-p-eNOS) in both the TA and VM muscles of mdx males 
and females (Fig. 4c, d; statistically significant for only the TA and VM muscles of mdx males, with p < 0.001 
and p < 0.01, respectively; two-way ANOVA with Bonferroni correction). Thus, we measured VEGF-A protein 
expression as a downstream signalling effect of eNOS-dependent NO production55. BCAAem supplementation 
was able to increase VEGF-A expression in the muscles of male mdx mice, with statistical significance observed 
in the VM muscles (p < 0.05, two-way ANOVA with Bonferroni correction) (Fig. 4a, b). VEGF-A levels were 
significantly higher in the TA (p < 0.05, two-way ANOVA with Bonferroni correction) and VM (p < 0.001; 
two-way ANOVA with Bonferroni correction) muscles of BCAAem-treated mdx mice than in untreated females 
(Fig. 4a, b). All these data suggest that BCAAem promotes eNOS and VEGF expression in the skeletal muscles 
of mdx mice.
BCAAem treatment ameliorates vascular rarefaction in the muscles of mdx mice. Thus, we 
examined the effect of BCAAem supplementation on blood vessels in the skeletal muscles of mdx (n = 10), 
C57BL6/J (n = 10), and eNOS−/− (n = 10) mice. Each experimental group was composed of 5 male and 5 female 
mice. We measured vascular density by CD31 staining as a marker of capillary networks, followed by quantifi-
cation of both total CD31+ blood vessels and CD31+ vessel-to-fibre ratio. As previously demonstrated22,40,43, the 
CD31+ vessel-to-fibre ratio and the CD31+ vessels/section ratio were lower in the muscles of the mdx mice than in 
the muscles of the control C57BL6/J mice (the decrease was ~56% in the TAs and ~18% in the VMs of both male 
and female animals) (Fig. 5). Notably, the CD31+ vessels/section ratio was substantially lower in both the TA and 
VM muscles of eNOS−/− mice than in C57BL6/J mice, although the CD31+ vessel-to-fibre ratio was not different 
in the muscles of these two genotypes (Fig. 5). BCAAem supplementation increased the CD31+ vessel-to-fibre 
ratio in both the TA and VM muscles of male and female mdx mice (Fig. 5). Except for an increase in the CD31+ 
vessels/section ratio in the VM (not statistically significant) and TA (p < 0.001, one-way ANOVA with Bonferroni 
correction) muscles of BCAAem-treated compared to the values observed for untreated C57BL6/J mice, no differ-
ences were observed in either type of muscle in eNOS−/− mice of either sex with or without amino acid treatment 
(Fig. 5). These results suggest a pivotal role for eNOS in mediating the effect of BCAAem on endothelial compart-
ments. To analyse the effect of BCAAem on the vessel structures of dystrophic skeletal muscles, we performed in 
vivo probe-based confocal laser endomicroscopy (p-CLE) to examine the expression of CD31 and the mural cell 
marker α-SMA. This analysis showed that few pericytes covered blood vessels in the TA muscles of both male and 
female mdx mice, thus indicating immature vessel architecture (Fig. 6a). In BCAAem-treated mdx mice, the vas-
cular architecture of TA muscles was less chaotic and complex, exhibiting improved vessel coverage by pericytes. 
This result the existence of mature vessels, as confirmed by an increase in the number of α-SMA+ cells (Fig. 6c). 
We also analysed vessel morphology in the TA muscles of mdx mice by p-CLE analysis of VE-cadherin and CD31 
expression (Fig. 6b). The TAs of untreated mdx mice showed irregular vessel walls, whereas the TA muscles 
of BCAAem-treated male mdx mice showed highly uniform alignment of the VE-cadherin+ vessels (Fig. 6b). 
Quantification of fluorescence signals showed that the CD31+, α-SMA+, and VE-cadherin+ cell numbers were 
statistically higher in the skeletal muscles of BCAAem-treated mice of both sexes (Fig. 6c). These data indi-
cate that amino acid supplementation can improve vessel structure in the skeletal muscles of BCAAem-treated 
dystrophic males and females.
BCAAem ameliorates the vascularization of dystrophic muscles via bone-marrow-derived 
endothelial progenitors. Next, we sought to identify the cellular mechanisms involved in the amelioration 
of skeletal muscle vascularization in dystrophic mice subjected to amino acid supplementation. Thus, the effect of 
BCAAem on the recruitment of circulating endothelial progenitors (EPs) to muscles was analysed56. We measured 
the number of SCA1+ CD34+ EPs in both muscle and blood of BCAAem-treated and untreated C57BL6/J, mdx, 
and eNOS−/− mice. The number of SCA1+ CD34+ EPs was higher in the peripheral blood of BCAAem-treated 
mice of all genotypes (Fig. S4a; p < 0.0001). This result suggests that BCAAem supplementation promotes specific 
mobilization of SCA1+ CD34+ EPs from bone marrow (BM). Then, we analysed the presence of SCA1+ CD34+ 
EPs in the TA and VM muscles of untreated and treated animals (Fig. S4b, c). BCAAem treatment promoted a 
statistically significant increase in the number of SCA1+ CD34+ EPs in the muscles of wild-type C57BL6/J and 
dystrophic mdx mice (Fig. S4b,c, p < 0.05). eNOS−/− mice did not exhibit any statistically significant increase 
in EP levels in the TA (Fig. S4b, p > 0.05) and even exhibited a statistically significant decrease in EP levels in 
the VM (Fig. S4c, p < 0.0001). To test the hypothesis that SCA1+ CD34+ EPs were present in the muscles of 
BCAAem-treated C57BL6/J and mdx mice due to mobilization of the EPs from BM, we performed BM trans-
plantation experiments, followed by BCAAem treatment (1.5 mg/g body weight for 14 days). Lethally irradiated 
C57BL6/J (n = 10) and mdx (n = 10) mice were transplanted with BM cells isolated from wild-type EGFP mice. 
BM engraftment efficiency was tested six weeks after the transplant, evaluating by FACS the percentage of EGFP+ 
cells in peripheral blood. The percentage of circulating EGFP+ cells in transplanted animals was >75% of the 
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Figure 4. BCAAem administration increases eNOS, ERα and VEGF levels in dystrophic muscle tissue of mdx 
mice. Cropped image of a representative western blot showing the expression of the ERα, eNOS, VEGF and 
vinculin proteins in VM and TA muscle tissues of and untreated male and female mdx mice (representative VM 
and TA samples of two BCAAem-treated males and two BCAAem-treated females and one representative VM 
sample of untreated mice of each sex are shown). Full-length blots are presented in Supplementary Fig. S9. (a) 
Densitometric analyses are shown as the ERα/vinculin ratio, eNOS/vinculin ratio and VEGF/vinculin ratio. 
(b) Cropped image of a representative western blot (c) and densitometric analysis (d) of p-eNOS and vinculin 
proteins VM and TA muscle tissues of BCAAem-treated and untreated in male and female mdx mice. Full-
length blots are presented in Supplementary Fig. S10. VM muscle of an untreated mdx mouse was used as a 
control. Data are shown as p-eNOS/vinculin ratios. All these experiments were performed three times. All data 
are presented as the mean ± s.e.m. Statistical error analysis was performed by two-way ANOVA with Bonferroni 
correction; *p < 0.05, **p < 0.01 and ***p < 0.001 indicate comparisons that reflect significant differences 
relative to the untreated group.
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total cells in both the C57BL6/J and mdx genotypes. Hereafter, the EGFP BM-transplanted animals are referred as 
C57BL6/J-EGFP and mdx-EGFP. After 8 weeks, the time needed for long-term BM reconstitution, these animals 
were supplemented or not with BCAAem (n = 5 per group) and sacrificed after an additional 15 days. We found 
a statistically significant increase in the number of SCA1+ CD34+ EGFP+ EPs in the blood and skeletal muscles 
of BCAAem-treated C57BL6/J-EGFP and mdx-EGFP mice compared to the number of such EPs observed in the 
untreated controls (Fig. 7a–c, p < 0.05). To elaborate, we observed a ~10-fold increase in the number of SCA1+ 
CD34+ EGFP+ EPs in the TA and VM muscles of BCAAem-treated mdx-EGFP mice compared with the number 
of such EPs in untreated mice (untreated 0.033% vs. treated 0.375% in TA; untreated 0.03% vs. treated 0.2% in VM; 
p < 0.05). Moreover, the number of CD31+ EGFP+ and CD90+ EGFP+ ECs increased in the blood and muscles 
of BCAAem-treated mdx-EGFP mice (Fig. 7a–c). Together, these data strongly suggest that BCAAem supple-
mentation stimulates the muscle homing of EPs and the muscular levels of ECs in dystrophic mice. To further 
support the hypothesis that BCAAem promotes EP migration from BM to skeletal muscles, the key chemotactic 
system that promotes angiogenesis was investigated. CXC chemokine receptor 4 (CXCR4) is an alpha-chemokine 
receptor that is specific for stromal cell-derived factor 1 (SDF-1), which is exhibits potent chemotactic activity 
in various cell types. Moreover, the SDF-1/CXCR4 interaction was found to contribute to the regulation of EP 
recruitment in ischaemic and damaged muscle tissues57,58. We observed a statistically significant increase in the 
levels of CXCR4+ EGFP+ cells, mobilized from the transplanted BM, and SDF1+ EGFP- resident cells in the 
TA muscles of BCAAem-treated mdx-EGFP and BCAAem-treated C57BL6/J-EGFP mice (Fig. 7d, p < 0.0001). 
Based on the muscular vessel amelioration observed in BCAAem-treated mdx mice, we identified a statistically 
significant increase in the number of CD31+ vessels per muscle fibre and in the level of α-SMA+ cells (two-fold 
increase, p < 0.0001) in the TA muscles of BCAAem-treated mdx-EGFP mice (Fig. 8). Notably, EGFP+ cells were 
found in the interstitial space and inside small CD31+ vessels (Figs 8 and 9). We found that EGFP+ cells had 
incorporated into the endothelium of small caliber vessels as revealed by coexpression of GFP and endothelial 
marker CD31 (Figs 8 and 9). The merger of GFP and CD31 staining patterns reveals colocalization (grey color) 
Figure 5. BCAAem treatment increases the number of CD31+ vessels in the muscles of mdx mice. 
Cryosections of VM (a) and TA (b) muscle tissues of BCAAem-treated and untreated male and female 
C57BL6/J, mdx and eNOS−/− mice were analysed by immunofluorescence staining for CD31 and laminin (5 
males and 5 females for each experimental group). Nuclei were stained with DAPI. Analysis of the VM and TA 
muscles of BCAAem-treated male and female mdx mice demonstrates an increase in the number of CD31+ 
vessels per fibre and per section. Scale bar, 100 µm. Quantification of CD31+ vessels per fibre and per section of 
VM (c) and TA (d) is shown. All data are presented as the mean ± s.e.m. Statistical error analysis was performed 
by one-way ANOVA with Bonferroni correction; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 
indicate significant differences from the untreated group.
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in vessel structures (Figs 8 and 9). The number of EGFP+ cells that exhibited CD31 was significantly higher in 
TA and VM muscles of BCAAem-treated mdx-EGFP (12,80 ± 0,58/section and 11,20 ± 0,86/section vs. untreated 
8,75 ± 0,85/section and 6.6 ± 0,67/section respectively; p < 0.05 and p < 0.01 one-way ANOVA Bonferroni) and 
in TA muscle of BCAAem-treated C57BL6/J-EGFP mice (20,30 ± 1,45/section vs. untreated 10,0 ± 1,14/sec-
tion; p < 0.0001 one-way ANOVA Bonferroni). No significant differences were observed between VM muscle of 
BCAAem-treated and untreated C57BL6/J-EGFP mice (11,27 ± 1,28/section vs. untreated 9,9 ± 0,74/section). The 
localization of EGFP+ cells confirms the effective presence in circulating blood of BCAAem-mobilized cells and 
colonization of the vessel walls by these cells. Histological and biochemical analyses of the TA and VM muscles 
of BCAAem-treated mdx-EGFP mice showed amelioration of the dystrophic muscle phenotype in terms of mean 
CSA values in the VM muscles (BCAAem-treated vs. untreated, 2203 ± 37 μm2 vs. 2704 ± 43 μm2, p < 0.0001) 
(Fig. S5). A similar trend was observed in the TAs of mdx-EGFP mice (BCAAem-treated vs. untreated, 2010 ± 32 
μm2 vs. 2061 ± 32 μm2) (Fig. S5). Furthermore, the endothelial differentiation potential of BM-derived EPs iso-
lated by FACS from BCAAem-treated mdx-EGFP mice was statistically higher than that of EPs obtained from 
untreated mdx-EGFP mice (p < 0.0001 one-way ANOVA Bonferroni) (Fig. S6). Taken together, these findings 
suggest that BCAAem supplementation induces the recruitment of BM-derived EPs in the skeletal muscles of 
mdx mice via the SDF-1-CXCR4 axis.
Amelioration of muscle dysfunction in mdx-EGFP mice subjected to BCAAem supplementa-
tion. BCAAem-treated and untreated mdx-EGFP and C57BL6/J-EGFP mice were tested for motor capacity, 
specific force, and fatigue index as previously described. BCAAem-treated mdx-EGFP mice showed statistically 
significant enhancement of time to exhaustion and endurance compared to untreated mdx-EGFP mice (Fig. S7). 
In these experiments, the running performance of the BCAAem-treated mdx-EGFP mice was approximately 75% 
higher than that of the untreated mice (Fig. S7). Statistically significant differences were observed in the fatigue 
indices of BCAAem-treated and untreated mdx-EGFP mice (Fig. S7).
Discussion
In this study, we have reported that dietary supplementation with a specific amino acid formulation (BCAAem) induces 
an increase in oxidative muscle fibre content and has an angiogenic effect in the muscles of mdx mice to ameliorate 
dystrophic symptoms, especially in females. Mdx is a murine model of DMD that is characterized by pathological sim-
ilarities to the human disease59–62. BCAAem enhances the oxidative myofibre content of skeletal muscles and increases 
eNOS activation (p-eNOS) and ERα and VEGF expression. These processes are accompanied by muscle recruitment 
of EPs, which ameliorates capillary density in skeletal muscles and increases the endurance time of BCAAem-treated 
dystrophic mdx mice. The major clinical symptoms of DMD are caused by dystrophin loss, which leads to sarcolemmal 
fragility and consequent muscle wasting63. DMD remains an incurable muscular disorder, and the proposed replace-
ment of the dystrophin gene is associated with multiple technical problems and only few and limited positive results. 
Furthermore, the signalling pathways involved in DMD, especially the regulation of oxidative metabolism in dystrophic 
skeletal muscle, are far from being well understood. Glycolytic muscle fibres are more susceptible to dystrophic damage, 
thus therapeutic strategies to increase oxidative fibre content have been proposed for DMD17–20. Our present findings 
Figure 6. BCAAem treatment leads to amelioration of vessel architecture in muscles of mdx mice. Probe-based 
confocal laser endomicroscopy was performed in TAs of BCAAem-treated and untreated male and female mdx 
mice. Treated and untreated mdx mice were injected with CD31 Alexa-Fluor 488 and α-SMA Alexa-Fluor 647 
(n = 5 per group) (a) and with CD31 Alexa-Fluor 488 and VE-cadherin Alexa-Fluor 647 (n = 5 per group) (b). 
Representative images show increased α-SMA+ pericyte vessel coverage and aligned VE-cad+ cells organized 
in regular wall structures. Scale bar, 200 µm. Quantification of the number of CD31+ vessels and α-SMA+ 
and VE-cad+ cells per field of view of the muscles of BCAAem-treated and untreated male and female mice 
is shown. (c) All data are presented as the mean ± s.e.m. Statistical error analysis was performed by two-way 
ANOVA with Bonferroni correction; *p < 0.05, ****p < 0.0001 indicate comparisons that reflect significant 
differences relative to the untreated group.
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demonstrate that dietary BCAAem consumption for 15 consecutive days reduces the extreme CSA distribution of the 
muscle fibres of mdx mice, suggesting that a change in muscular metabolism occurs. We analysed the fibre composition 
of the skeletal muscle via three different approaches, demonstrating that BCAAem induces an increase in oxidative 
myofibre content, with MyHC IIx expression in both the VM and TA muscles of BCAAem-treated mdx male and 
female mice. These findings are consistent with those reported in previous studies by us and other researchers42,64 on the 
ability of BCAAem to upregulate PGC-1α and SIRT1 expression and activity in skeletal muscle and on the roles of 
PGC-1α and ERα as key transcriptional regulators of the change in fibre type in skeletal muscle. Skeletal muscle, in fact, 
is an oestrogen-responsive tissue that expresses high levels of ERα mRNA. ERα drives muscle regenerative capacity, the 
expression of MyHC isoforms and resistance to fatigue65. Furthermore, the described PGC-1α-dependent changes in 
myofibre composition are mediated by the oestrogen receptor66,67. Accordingly, we first demonstrated a stronger and 
more consistent change in MyHC IIx expression in female BCAAem-treated mdx mice than in male BCAAem-treated 
mdx mice, with significantly higher expression of ERα. Since ERα stimulation also promotes vessel remodelling via 
eNOS expression42,54, we tested the hypothesis that the BCAAem-induced change in fibre type is accompanied by an 
Figure 7. BCAAem promotes the mobilization of donor bone marrow-derived EGFP endothelial progenitors 
to dystrophic muscles. Bone marrow (BM) of donor C57BL6/J-EGFP mice was transplanted into lethally 
irradiated host C57BL6/J and mdx mice (referred to after transplantation as C57BL6/J-EGFP and mdx-EGFP 
mice). BM-transplanted animals were treated with BCAAem and compared to untreated animals. Flow 
cytometric analysis of SCA1+ CD34+ EGFP+ EPs and CD31+/CD90+ EGFP+ endothelial cells (ECs) was 
performed in blood (a) and in TA (b) and VM (c) muscle tissue isolated from BCAAem-treated and untreated 
C57BL6/J-EGFP and mdx-EGFP mice (n = 5 for each experimental group). FACS analysis of CXCR4+ EGFP+ 
and SDF-1+ cells (d) is shown in TA muscle of C57BL6/J-EGFP and mdx-EGFP mice. Quantification of EGFP+ 
cells is shown as percentage of total isolated cells for TA and VM. The increase in the number of EPs in the 
muscles of BCAAem-treated mdx-EGFP mice demonstrates that BCAAem supplementation stimulates muscle 
homing of BM stem cells. The muscle homing effect of BCAAem is supported by the increase in the levels of 
CXCR4+/EGFP+ and SDF-1+ cells (n = 5 for each experimental group). Individual data are shown in the 
graphs, and the line indicates the mean value. Statistical error analysis was performed by two-way ANOVA with 
Bonferroni correction; *p < 0.05, **p < 0.01, and ****p < 0.0001 indicate comparisons that reflect significant 
differences relative to the untreated group.
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angiogenic muscle response. The absence of dystrophin in DMD causes nNOS displacement from the sarcolemmal 
membrane, and the consequent reduction of NO production causes vasoconstriction and abnormal blood flow during 
skeletal muscle contraction25. Moreover, dystrophin normally forms a complex with eNOS in ECs, and consequently, 
in mdx mice, NO production is markedly compromised in ECs, with impaired angiogenesis observed in muscles68. 
Accordingly, a reduced number of CD31+ vessels were observed in the muscles of dystrophic mdx mice compared with 
the number observed in healthy C57BL6/J mice, and notably, BCAAem supplementation increased the number of 
CD31+ vessels in the muscles of mdx mice, unlike what was observed in eNOS−/− mice. This effect was accompanied 
by consistent induction of eNOS and VEGF expression in the muscles of BCAAem-treated mdx mice. Furthermore, we 
have shown in vivo that BCAAem ameliorates the compromised vessel architecture in BCAAem-supplemented mdx 
mice by increasing the number of CD31/α-SMA and CD31/VE-cad double-positive vessels. These results suggest pro-
gressive maturation of the blood vessels and normalization of the capillary walls. Recently, higher expression of the 
eNOS protein was observed in the ECs of females than in those of males69, suggesting intrinsic sexual dimorphism of 
these cells. Accordingly, we demonstrated a greater increase in the number of CD31+ vessels in female 
BCAAem-treated mdx mice than in male BCAAem-treated mdx mice. These data, together with the stronger induction 
of VEGF and eNOS activation in female mice than in male mice, suggest that the differential response to BCAAem 
supplementation in terms of angiogenesis induction could be linked to a higher capacity of female muscle tissue to 
respond to BCAAem treatment due to sex-related differences. Consistent with the positive effects on muscle 
Figure 8. BCAAem recruits endothelial progenitors to healthy and dystrophic TA muscles. Cryosections of TA 
(a) muscle tissues of BCAAem-treated and untreated C57BL6/J-EGFP and mdx-EGFP mice were analysed by 
immunofluorescence staining for GFP, CD31 and laminin (Lam) (n = 5 for each experimental group). Nuclei 
were stained with DAPI. EGFP+ cells were detected in the interstitial spaces (arrowheads in a) and inside small 
CD31+ vessels (boxes in a). Magnification (X 1,000) of boxes indicate vessels expressing GFP (green), laminin 
(red), CD31 (purple). Merged images reveal vessel areas of costaining, as evidenced by the grey staining pattern. 
Analysis of the TA muscles of BCAAem-treated mdx-EGFP mice demonstrates an increase in the number of 
EGFP+ CD31+ and CD31+ vessels and α-SMA+ cells per section. Scale bar, 45 µm. The percentage of EGFP+ 
cells per section (b) and the number of EGFP+ CD31+ cells per section (c) are shown. The number of CD31+ 
vessels per fibre (d) and α-SMA+ cells per section (e) is shown. All data are presented as the mean ± s.e.m. 
Statistical error analysis was performed by one-way ANOVA with Bonferroni correction; *p < 0.05, **p < 0.01 
and ****p < 0.0001 indicate comparisons that reflect significant differences relative to the untreated group.
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performance demonstrated by the increase in oxidative fibre content in mice70–72, we observed an increased fatigue 
resistance in BCAAem-treated mdx mice. In addition, the increased vascular density and maturation observed in 
BCAAem-treated mdx mice are consistent with the improvement of the muscle performance of dystrophic mice, as 
previously reported73. To understand how BCAAem induces muscular vessel remodelling, we analysed the EP levels in 
the blood and muscles of healthy C57BL6/J, dystrophic mdx, and eNOS−/− mice. Interestingly, we found that the num-
ber of CD34+ SCA1+ EPs was higher in BCAAem-supplemented mice of all genotypes. In contrast, the number of 
CD34+ SCA1+ EPs was higher in the muscles of mdx mice but not C57BL6/J and eNOS−/− mice, which leads us to 
hypothesize that dystrophic muscle damage may influence the degree of vessel remodelling in response to BCAAem. 
Moreover, the absence of structural and density modifications of vessels in eNOS−/− mice further confirmed the key 
role of eNOS in mediating vessel remodelling in response to BCAAem treatment. To identify the origins of the EPs in 
dystrophic muscle tissues, EGFP-C57BL6/J BM was transplanted into C57BL6/J and mdx mice before amino acid sup-
plementation. BCAAem promoted a statistically significant increase in the number of EGFP+ SCA1+/CD34+ EPs in 
the TA and VM skeletal muscles of dystrophic mice compared to the number observed in C57BL6/J healthy animals. 
Moreover, the number of EGFP+ CD31+ and CD90+ ECs in the skeletal muscles was significantly higher in 
BCAAem-treated mice than in untreated mdx mice. Interestingly, the number of CD31+ capillaries per fibre in the 
muscles of BCAAem-treated and untreated BM-transplanted mice was higher than the number observed for 
non-transplanted mice, suggesting that donor BM endothelial progenitor cells were directly incorporated into the host 
vessels, thereby forming a mosaic pattern of BM progenitor-derived and locally derived CD31+ capillaries. Additionally, 
BCAAem may greatly influence the promotion of the muscle homing of BM EPs. These results were reinforced by the 
Figure 9. BCAAem recruits endothelial progenitors to dystrophic VM muscles. Cryosections of VM (a) muscle 
tissues of BCAAem-treated and untreated C57BL6/J-EGFP and mdx-EGFP mice were were immunostained for 
GFP, and costained for CD31 and laminin (lam) (n = 5 for each experimental group). Nuclei were stained with 
DAPI. EGFP+ cells were detected in the interstitial spaces (arrowheads in a) and inside small CD31+ vessels 
(boxes in a). Magnification (X 1,000) of boxes indicate vessels expressing GFP (green), laminin (red), CD31 
(purple). Merged images reveal vessel areas of costaining, as evidenced by the grey staining pattern. Scale bar, 
45 µm. Quantifications of EGFP+ cells (b) and EGFP+ CD31+ cells (c) in each section and CD31+ vessels 
per fibre (d) and α-SMA+ cells per section (e) are shown. All data are presented as the mean ± s.e.m. Statistical 
error analysis was performed by one-way ANOVA with Bonferroni correction; **p < 0.01 and ***p < 0.001 
indicate comparisons that reflect significant differences relative to the untreated group. Histograms correspond 
to: untreated (white) and BCAAem-treated (black).
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high number of circulating EPs (EGFP+ CD34+/SCA1+) and ECs (EGFP+ CD90+ and EGFP+ CD31+) in 
BCAAem-treated mice of all genotypes, suggesting the occurrence of EP mobilization from BM with subsequent accu-
mulation in skeletal muscles. Muscle homing of EPs was confirmed by the increased number of circulating EGFP+ 
CXCR4+ cells and concomitant expression of SDF-1 in the skeletal muscles of BCAAem-treated mdx mice. The angi-
ogenic potential of circulating EGFP+ EPs of BCAAem-treated mdx mice was also experimentally confirmed by show-
ing the capacity of these EPs to form endothelial colonies in vitro. These results suggest that the observed mobilization 
of EPs from BM to dystrophic skeletal muscle may depend on the muscular levels of VEGF, which may act as a regulator 
of SDF-166,67,74, and these results are consistent with previous reports25,27,73,75 showing the role of the SDF1/CXCR4 axis 
in the muscle recruitment of EPs. Overall, our data suggest that dietary supplementation with BCAAem could be an 
effective adjuvant treatment for human DMD because BCAAem changes the energy metabolism of muscles (i.e., 
increases oxidative muscle fibre content), ameliorates vascularization (i.e., increases capillary density) of skeletal mus-
cle, and increases muscle fatigue resistance in mdx mice.
Methods
Ethics statement and experimental model details. Procedures involving live animals conformed to 
Italian law (D.L.vo 116/92) and were subsequently approved by ethics committees. The in vivo experiments were 
authorized by the Ethical Committee of Università degli Studi di Milano, protocol number 10/13–2014/2015. 
Three-month-old normal (C57BL6/J), dystrophic (mdx C57BL6/10ScSn-DMDmdx/J), eNOS−/− (B6.129P2-
Nos3tm1Uncmice/J) and EGFP/C57BL6/J mice were all provided by Jackson Laboratory (USA). The weight of each 
C57BL6/J mouse was approximately 19 gr, while the weight of each mdx mouse was 25 gr. Animals were treated 
humanely, and animal cages were maintained in controlled ambient light (12-hour light, 12-hour dark) at tem-
peratures between 21 °C and 24 °C. The animals were able to move freely within the cages and had access to clean 
water and food. After 15 days of treatment with the BCAAem mixture, mice were sacrificed by cervical disloca-
tion according to Italian law. For surgical procedures, mice were anaesthetized with 2% Avertin (0.015 ml/kg body 
weight) by intra-peritoneal injection.
BCAAem mixture composition, dosage and absorption. BCAAem supplementation was performed 
for two weeks. BCAAem (1.5 mg/g body weight/day in drinking water, with percent composition of the mixture 
as previously detailed)42,76 was dissolved in tap water and stored at 4 °C before daily administration. Drinking 
water was provided in a graduated bottle placed on top of each cage, in which 2 mice were housed. The drinking 
bottle was connected to a sipping tube containing a metal ball to prevent leakage of water. The volume of water 
was measured daily throughout the treatment. The average volume of water consumed per mouse per day was 
calculated. Data were expressed as ml/animal/day. We measured the circulating BCAA (leucine, isoleucine, and 
valine) levels in wild-type (C57BL6/J) and mdx mice acutely (30–120 min) supplemented with BCAAem as pre-
viously described by D’Antona et al.42.
Immunohistochemistry and immunofluorescence. VM and TA muscles were removed from both the 
treated and untreated mice of each genotype described, frozen in liquid-nitrogen-cooled isopentane, embed-
ded in Tissue-Tek® O.C.T. compound (Sakura Finetek, USA) and sectioned in 10-mm-thin sections with 
a CM 1820 cryostat (Leica, Germany). Histological analyses were performed on the VM and TA muscles as 
these muscles show similar levels of dystrophic degeneration in mdx mice. Serial sections were stained with 
Haematoxylin and Eosin (H&E) and Azan-Mallory (AM) stain. Images were captured with a Leica DM6000 B 
(Leica, Germany) optical microscope. Quantification of fibre area was performed manually using NIH ImageJ 
software 6.0. Myofibrillar ATPase staining with pre-incubation at pH 4.3 was used to identify fibre types IIa, IIx 
and IIb in TA and VM muscles. ATPase (pH 4.3) staining was performed as described in recent publications77–79. 
After staining, the sections were washed with several changes of tap water, dehydrated with ethanol, cleared in 
xylene, and mounted in glycerol-gelatin aqueous slide mounting medium (Sigma-Aldrich, USA). SDH stain-
ing was performed in accordance to Bloemberg et al.80. Images were captured with a Leica AS LMD optical 
microscope. Quantification of different fibre types was performed using ImageJ software (NIH); 32-bit images 
were analysed by histogram distribution of grey values in the muscle-selected area, presented as pixel counts 
for each grey value. Values were then grouped in specific intervals according to different fibre types. For immu-
nofluorescence analysis, sections were fixed in 80% ethanol or 100% cold acetone and incubated with the fol-
lowing antibodies: rabbit anti-laminin (1:100; Sigma, Germany), rat anti-CD31 (1:50; BD, USA), anti-smooth 
muscle actin (1:50; Sigma-Aldrich, USA), rabbit anti-von Willebrand factor (vWF) (1:400; Dako, Denmark), 
mouse anti-VE-cadherin (1:50; Chemicon International, USA), mouse anti-MyHC fast (1:20; Hybridoma Bank, 
Stanford, California, USA) and mouse anti-MyHC slow (1:20; Hybridoma Bank, Stanford, California, USA). 
The sections were rinsed in phosphate-buffered saline (PBS) and incubated with the corresponding Alexa Fluor 
488, Alexa Fluor 594 or Alexa Fluor 647-conjugated secondary antibodies (1:100; Molecular Probes, Thermo 
Scientific, USA). To detect EGFP+ cells, slides were incubated with rabbit anti-GFP antibody (1:100; Molecular 
Probes, Thermo Scientific, USA). Cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Images 
were captured with a Leica TCS-SP2 confocal microscope. For quantitative analysis, NIH ImageJ software 6.0 was 
used. Vessel count was performed by evaluating the number of α-SMA+ vessels in at least three sections for each 
slide, while CD31+ capillaries were evaluated by acquiring at least seven images for each slide and by calculating 
the ratio between CD31+ capillaries and fibres.
Probe-based confocal laser endomicroscopy (p-CLE). CD31 Alexa Fluor 488, VE-cad Alexa Fluor 647 
(BioLegend, San Diego), and α-SMA Alexa Fluor 647 (Abcam, UK) (1 μg/g body weight) were injected via the 
tail vein, and the mice were shielded from light. Endomicroscopic imaging was performed 24 hours later with a 
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Cellvizio Dual Band endomicroscopy system (Mauna Kea Technologies) according to the manufacturer’s instruc-
tions, and images were acquired with Cellvizio software81. Mice were anaesthetized with 2% Avertin (0.015 ml/kg 
body weight), and muscles were exposed for CLE by a 3-mm skin incision. The confocal probe was inserted into 
the TA muscle to scan the tissue. Several incisions were then made to investigate deeper parts of the tissue. Mice 
were euthanized prior to recovery from anaesthesia.
In vivo muscle function assessment. Exercise capacity was assessed using an incremental treadmill 
exhaustion test, as previously described42. Briefly, each animal was placed on the belt of a 6-lane motorized tread-
mill (Exer 3/6 treadmill, Columbus Instruments, OH, USA) supplied with shocker plates, which could be indi-
vidually enabled or disabled for each lane. During each exhaustion test, the duration of the electrical stimulus was 
fixed at 200 ms, with a 0.34-mA amplitude, and 1-Hz repetition rate. After acclimatization, all mice were subjected 
to the initial treadmill exhaustion tests at a 0° inclination according to the following protocol: 5 min at 5 m/min, 
followed by an incremental increase in speed of 1 m/min until exhaustion. Exhaustion was achieved when the 
mice stayed on the shocker plate without attempting to reengage the treadmill for 20 s or more. Three tests were 
performed on each animal, allowing 4 days between each test. The values were averaged to obtain a single value 
per animal. In a second set of experiments, endurance was evaluated as the time spent on the treadmill belt run-
ning at 50% of the maximal velocity reached in the previous incremental exhaustion test (endurance time).
Ex vivo muscle function assessment. The method used for mechanical analysis of intact muscles has 
been previously described47. Briefly, the TA muscle of the right leg was dissected and placed in an organ bath 
filled with Krebs solution (120 mM NaCl, 2.4 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, 1.2 mM 
KH2PO4, and 24.8 mM NaHCO3; pH 7.4). The bath was bubbled with 95% O2 and 5% CO2 at a constant temper-
ature of 22 °C and attached to a force transducer (Radnoti organ bath system, AD Instruments). Electrical pulses 
were delivered through platinum electrodes connected to a stimulator (Tumiati, Italy). Tetanic isometric contrac-
tions were evoked (110 Hz, 500 ms, supramaximal amplitude) at the length at which the maximal isometric force 
was observed, and the twitch time to peak and maximal tetanic force (Tf) values were measured. Specific tetanic 
force (i.e., maximal tetanic force normalized to muscle volume; g/μL) was considered for comparisons among 
the different groups of animals. Further, the fatigue index was measured (and expressed in %) as the decrease in 
tetanic force at different stimulation frequencies (0.03, 0.09, and 0.3 Hz) compared to the maximal tetanic force47.
RT-PCR analysis. Total RNA was extracted from the muscles of male and female mdx mice with TRIzol (Thermo 
Scientific, USA) according to the manufacturer’s instructions. First-strand cDNA was prepared as previously 
described82. The following primers were used: MYH1-Fw 5′-ggaggaggaaatcgaggcag-3′, Rev 5′-cgctgatctcctccagttcc-3′; 
MYH2b-Fw 5′-gggtctgaactctgctgacc-3′, Rev 5′-tggcctttggtgacgtactc-3′; MYH4-Fw 5′-tgacgaccttgagctgacac-3′, 
Rev 5′-gggccttcttctccttggtc-3′; GADPH-Fw 5′-caaggctgtgggcaaggt-3′, Rev 5′-ggcaggtcagatccacaactg-3′. The 
expression levels of each gene were measured using SYBR Green (GoTaq PCR Master Mix; Promega, Madison, 
USA). Analyses were performed on duplicate cDNA samples from different muscle samples. Threshold cycle (Ct) 
values of target genes were normalized against that of the housekeeping gene glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH), and relative transcript levels were calculated from the Ct values as X = 2−Δct, where X is the 
fold difference in amount of target gene versus the amount of GAPDH, and ΔCt = Cttarget − CtGAPDH.
Bone marrow transplantation. Recipient mice were lethally irradiated at 8.5 Gy 20 hours before transplant. 
Under sterile conditions, bone marrow cells (BMCs) were isolated by smashing the femurs of EGFP/C57BL6/J 
mice in PBS and were purified by Histopaque®-1077 (Sigma-Aldrich, USA) according to manufacturer’s instruc-
tions. BMCs were pooled from at least 3 independent donors, and 1.5 × 106 cells were injected into the tail veins 
of lethally irradiated mice, either C57BL6/J or C57BL6/10ScSn-DMDmdx/J. The irradiation efficiency was mon-
itored without reconstituting one mouse for each strain. These sentinels died after 15 days. At sacrifice, the per-
centage of EGFP+ cells in blood and TA/VM muscles was evaluated by FACS, and the cells were analysed for 
co-expression of Sca-1, CD34, CD31, CD90, CXCR4 and SDF-1.
Western blot analysis. BMCs were lysed in RIPA buffer (50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% 
Na-deoxycholate, 150 mM NaCl, 1 mM EDTA). Muscle samples were lysed in RIPA buffer with a tissue homog-
enizer. Total protein concentrations were determined by the BCA assay, and measurements were made with 
a Glomax microplate luminometer (Promega, USA). Samples were resolved on an 8% polyacrylamide gel and 
transferred to supported nitrocellulose membranes (Bio-Rad Laboratories). Next, the membranes were blocked 
in 5% milk dissolved in TBS-T (20 mM Tris, 150 mM NaCl and 0.1% Tween 20). Then, the membranes were 
incubated overnight at 4 °C with primary antibodies against the following targets: p-eNOS (Ser1177) (cod 9571, 
Cell Signaling, USA), eNOS (cod 9572, Cell Signaling, USA), ERRα (cod sc-787, Santa Cruz, USA), VEGF (cod 
sc-507, Santa Cruz, USA), and vinculin (Sigma-Aldrich, USA). Then, the membrane was washed extensively with 
TBS-T, probed with horseradish peroxidase (HRP)-conjugated secondary antibodies (Dako, USA) and developed 
with ECL (Amersham Biosciences, Italy). Each experiment was performed on at least three different mice for each 
experimental condition. Densitometric analyses were performed using NIH ImageJ software.
Evaluation of myosin heavy chain (MyHC) isoforms. Muscle samples were lysed in SDP buffer (10% 
sodium dodecyl phosphate, 40 mM dithiothreitol (DTT), 5 mM EDTA, 0.1 M Tris (pH 8)) with a tissue homog-
enizer. Total protein concentration was determined by the BCA assay and quantified with a Glomax microplate 
luminometer (Promega, USA). Samples were resolved on a 6% polyacrylamide-30% glycerol gel at 4 °C for 24 hours 
and subjected to standard Coomassie Blue staining, and images were acquired with an Odyssey® imaging system 
(LI-COR, Nebraska, USA) and Image Studio Lite version 5.2. Densitometric analyses were performed with NIH 
ImageJ software. Each experiment was performed on at least three different mice for each experimental condition.
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Statistics. For histograms, data are expressed as the mean ± s.e.m. In the box and whisker plots, boxes indi-
cate 25th to 75th percentiles; whiskers indicate 5th to 95th percentiles; and the line indicates the median. To com-
pare the means of multiple groups, one-way or two-way ANOVA was used in the Prism 6 software (GraphPad 
software, La Jolla, CA) with Bonferroni correction. The difference among groups was considered significant at 
p < 0.05.
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